




- (51) **International Patent Classification:**
C12N 15/86 (2006.01) C12N 15/10 (2006.01)
- (21) **International Application Number:**
PCT/IB2021/061943
- (22) **International Filing Date:**
17 December 2021 (17.12.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/199,368 21 December 2020 (21.12.2020) US
63/263,924 11 November 2021 (11.11.2021) US
- (71) **Applicant: PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).
- (72) **Inventors: KALLA, Neha;** c/o Pfizer Inc., 7030 Kit Creek Rd., Morrisville, North Carolina 27560 (US). **KISH, William;** c/o Pfizer Inc., 7030 Kit Creek Rd., Morrisville, North Carolina 27560 (US). **LIGHTHOLDER, John;** c/o Pfizer Inc., 7030 Kit Creek Rd., Morrisville, North Carolina 27560 (US). **LIU, Zhuo;** c/o Pfizer Inc., 7030 Kit Creek Rd., Morrisville, North Carolina 27560 (US). **VORST, Eric;** 319 View Dr., Morrisville, North Carolina 27560 (US).
- (74) **Agent: ZIELINSKI, Bryan C.;** Pfizer Inc., 235 East 42nd Street, MS 235/9/86, New York, New York 10017 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) **Title:** METHODS AND COMPOSITIONS FOR INHIBITING EXCESS NUCLEIC ACID PRECIPITATION



(57) **Abstract:** The present disclosure describes improved methods for use in purifying biological products made by host cells. In some embodiments, the improved methods comprise one or more steps of lysing host cells, such as with a detergent, to release the biological product, precipitating host cell DNA, such as with domiphen bromide, and then inhibiting precipitation of residual host cell DNA in a supernatant containing the biological product by adding a salt to a sufficient final concentration. In some embodiments, the biological product is a vaccine, or a viral vector for gene therapy, such as an AAV vector or a lentiviral vector.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*